AARTIDRUGS
OVERVALUEDAarti Drugs Limited
Healthcare · NSE
↓ 25.0% vs fair value
52W Low
₹319
+22.1% from low
52W High
₹564
-31.0% from high
Valuation Gauge
Current Price
₹389
Fair Value
₹312
Fair Value Analysis
₹312
Based on free cash flow projections and balance sheet strength analysis and earnings growth potential for Healthcare sector companies | Sector-cheap: P/E at 28th percentile vs sector peers. | CAUTION: ROCE declining (latest 14.6%) — returns on capital are falling; verify this isn't a value trap.
Cash Flow Analysis
40% weight
Balance Sheet Value
20% weight
Growth Valuation
40% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Solid Fundamentals
Profitability
ROE of 9.3% is acceptable for Healthcare sector (benchmark: 15%)
Debt & Leverage
D/E ratio of 0.4x is well within the Healthcare sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 24.6x trades at a 85% discount to Healthcare sector median (160x) — attractively valued
Cash Flow
FCF margin of 2.8% — thin cash generation, watch capex trends
Earnings Growth
5yr EPS CAGR of -6.4% — earnings are declining (sector avg growth: 18.7%)
Dividend
Dividend yield of 0.5% provides moderate shareholder returns
Sentiment Trend — Last 30 Days
Historical Returns
Key Financials
EPS (TTM)
₹14.9
P/E Ratio
24.6x
P/B Ratio
2.3x
ROE
9.3%
ROCE
14.3%
Debt / Equity
0.39x
Beta
0.36
Div Yield
0.5%
FCF (Cr)
₹67 Cr
Revenue (Cr)
₹2,369 Cr
EPS Growth 5Y
-6.4%
Mkt Cap (Cr)
₹3,356 Cr
52W High
₹564.1
52W Low
₹319
Book Value/Share
₹159
Financial History
Annual P&L data not available yet.
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant